laurademing
I publish concise, analytically minded posts that bridge technical science and long-horizon investment themes. Content ranges from meetup invitations and engineering hires to observations about organ-rewarming devices and portfolio milestones.
Past bets that played out
Most recent standout call is non-market: an invitation to a small Galois/group theory meetup in San Francisco. Posts often include technical or community-oriented items rather than immediate tradeable signals.
A private biotech (Until Labs) announced a large funding round ($58M Series A; claims $100M+ raised to date) to develop reversible cryopreservation of human organs, initially targeting transplant logistics/organ viability with a longer-term ambition toward whole-body cryopreservation/“hibernation pods.” This is an early-stage, long-duration scientific/engineering roadmap; near-term public-market actionability is limited because the company is private and there are no directly referenced public c
A private biotech (Until Labs) announced a large funding round ($58M Series A; claims $100M+ raised to date) to develop reversible cryopreservation of human organs, initially targeting transplant logistics/organ viability with a longer-term ambition toward whole-body cryopreservation/“hibernation pods.” This is an early-stage, long-duration scientific/engineering roadmap; near-term public-market actionability is limited because the company is private and there are no directly referenced public c
Non-market content: an invitation to a small meetup about Galois/group theory in San Francisco. No finance, macro, company, or ticker-relevant information provided.
What this channel is watching now
Top active ticker: SF (mentioned once) with average conviction 0.6. Coverage here is limited — current output leans toward thematic, science-driven observations and community notes rather than frequent tradable recommendations.
Latest videos and market context
No video content available. Recent posts consist of short text threads and links about meetups, engineering hires, device proof-of-concepts, and a portfolio milestone (FDA approval) without company identifiers.
Laura 🌲 ⛰️ @LauraDeming Jul 9 Does anyone have good recs for probability / stats tutors? 16 2 45 33K
A tweet asking for recommendations for probability/statistics tutors; contains no market, company, macro, or sector information.
Hello! I'd like to host a small 'let's understand Galois / group theory' meetup in SF. If you've ever spent hours sta...
Non-market content: an invitation to a small meetup about Galois/group theory in San Francisco. No finance, macro, company, or ticker-relevant information provided.
ship devices that transform biology, join the engineering team at Until - https://t.co/Tc4wvGlxhk
The source is a job/engineering recruiting post for “Until” about shipping biology-transforming devices. It contains no market-relevant details (no product specs, customers, funding, timelines, partnerships, financials) and no public-company references/tickers.
getting through the danger zone for ice formation in under a minute, with a device that only draws a few kW (work don...
Post describes a proof-of-concept device that can traverse the “danger zone” for ice formation in <1 minute while drawing only a few kW, demonstrated on a pig kidney (human-scale). If reproducible and scalable, this points to improved organ preservation/rewarming (less ice crystal damage), potentially expanding viable transplant logistics and increasing transplant volumes over time. No company/ticker is named; investability is therefore thematic and longer-horizon.
Proof-backed call history
Recent posts include: a Galois/group theory meetup invitation in San Francisco; an engineering recruiting post for Until focused on shipping biology-transforming devices; an observation about a proof-of-concept device that rapidly traverses the ice-formation danger zone in organ rewarming; and an announcement celebrating a ‘first FDA approval’ for a company in the author's portfolio (no company named).
A private biotech (Until Labs) announced a large funding round ($58M Series A; claims $100M+ raised to date) to develop reversible cryopreservation of human organs, initially targeting transplant logistics/organ viability with a longer-term ambition toward whole-body cryopreservation/“hibernation pods.” This is an early-stage, long-duration scientific/engineering roadmap; near-term public-market actionability is limited because the company is private and there are no directly referenced public c
A private biotech (Until Labs) announced a large funding round ($58M Series A; claims $100M+ raised to date) to develop reversible cryopreservation of human organs, initially targeting transplant logistics/organ viability with a longer-term ambition toward whole-body cryopreservation/“hibernation pods.” This is an early-stage, long-duration scientific/engineering roadmap; near-term public-market actionability is limited because the company is private and there are no directly referenced public c
Non-market content: an invitation to a small meetup about Galois/group theory in San Francisco. No finance, macro, company, or ticker-relevant information provided.
About this channel
laurademing (@laurademing) posts concise, scientifically informed commentary and community notes. Content frequently highlights engineering and biology topics with longer-horizon thematic implications rather than immediate, actionable market-level claims.
@laurademing
Most recognized assets
Unlock the full track record
Follow @laurademing for short-form, science-forward commentary and occasional community invites. Expect thematic observations and technical notes rather than frequent tradable calls.